Plasmatic Concentrations of Propofol and Remifentanil in Obese and Non Obese Patients.

• Status: Completed
• Trial end date: 2021-05-25
• Target enrollment: 0
• Participant gender: All

Summary

This prospective monocentric phamacokinetics study aims to compare plasmatic concentrations of Propofol and Remifentanil required to target a specific range of monitored anesthesia and analgesia during sus-mesocolic surgery in obese and non obese patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Treatments: Propofol; Remifentanil

Criteria

Inclusion Criteria:

Obese patients group:

• Age ≥ 18 years old

• Severe and morbidly obese patients (35kg / m2≤IMC <55kg / m2).

• Patients undergoing general anesthesia for laparoscopic susmesocolic surgery (bariatric surgery or cholecystectomy).

• Patients who have given their consent in the manner described by the public health law of August 9, 2004.

• Patients benefiting from a Social Security scheme.

Group of non-obese patients:

• Age ≥ 18 years old

• Patients with normal weight or slightly overweight (19- Patients receiving general anesthesia for laparoscopic susmesocolic surgery (cholecystectomy).

• Patients who have given their consent in the manner described by the public health law of August 9, 2004.

• Patients benefiting from a Social Security scheme.

Exclusion Criteria:

• Patient refusal

• Age <18 years old

• Protected adults and vulnerable persons

• Pace maker

• General anesthesia in the 24 hours preceding this surgery

• Proven or suspected dysautonomia

• Premedication by gabapentin Neurontin °

• Locoregional peri-medullary analgesia technique used concomitantly during the pre- and intraoperative period.

• Unbalanced dysrhythmic heart disease (AC / FA; extrasystoles; non-sinus rhythm)

• Pregnant or breastfeeding woman

• Intubation impossible planned

• Hypersensitivity to the products used

• Allergy to peanut or soy